atai Life Sciences
@atai_life
Followers
12,136
Following
504
Media
353
Statuses
1,183
Healing #mentalhealth disorders so that everyone everywhere can live a more fulfilled life. Interested in #psychedelics & #drugdevelopment . $ATAI CEO @FloBrand .
Berlin, Germany
Joined June 2018
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#母の日
• 224389 Tweets
#MothersDay
• 137704 Tweets
ヴィクトリアマイル
• 131981 Tweets
ストフェス
• 58861 Tweets
テンハッピーローズ
• 53769 Tweets
Chivas
• 43628 Tweets
カーネーション
• 39961 Tweets
Roger Corman
• 37014 Tweets
ナミュール
• 35804 Tweets
マスクトディーヴァ
• 30546 Tweets
Loma
• 25718 Tweets
WIN5
• 25648 Tweets
フィアスプライド
• 19360 Tweets
津村騎手
• 16939 Tweets
ツムツム
• 15495 Tweets
#SHOWチャンネル
• 13788 Tweets
ヴェルディ
• 11303 Tweets
G1初制覇
• 10779 Tweets
ライラック
• 10693 Tweets
ウンブライル
• 10261 Tweets
Pinned Tweet
Ring that bell
@atai_life
! So much pride for this team.
This is us, ATAI on NASDAQ. We think it has a nice ring to it.
102
79
224
We can change things. A future where families, friends, parents, sons, and daughters that we love have access to the help that they need. It’s the only future we will accept. And today, that future is one day closer.
9
45
310
Interesting comments from
@elonmusk
at leading global tech conference
#CODECON
: "I think generally people should be open to psychedelics"
#openyourmind
#psychedelics
$ATAI
9
28
109
Today, we announce our Series D fundraising, successfully raising an additional $157m to progress our mission of healing mental health disorders.
Read more:
10
23
97
What an incredible announcement from one of our strategic investments,
@COMPASSPathway
! Today, COMPASS shared the news that the company has dosed the last patient in its phase 2b study “Psilocybin Therapy for Treatment-Resistant Depression”.
0
4
63
Today, all of us are extremely proud to share with you the closing of our Series C financing round. We believe that this reflects the growing recognition for more effective treatments in mental health.
Plenty more to come in the future. 🙂
#mentalhealth
5
7
56
UPDATE: atai increases ownership in
@COMPASSPathway
to 20.8%. Demonstrating our strong confidence in COMPASS, its milestone P2b
#COMP360
#psilocybin
data & its future in
#psychedelics
#mentalhealth
#innovation
See:
2
9
50
2 weeks ago we celebrated our IPO, a huge step for atai and an incredible team accomplishment. Our work continues with greater focus than ever, so that everyone, everywhere can live a more fulfilled life.
3
9
49
Congratulations
@RickDoblin
, Amy Emerson, and the entire team at
@MAPS
for submitting an NDA (New Drug Application) to the FDA for MDMA-assisted therapy for the treatment of PTSD.
If approved, this would be the first FDA-approved psychedelic-assisted therapy, paving the way for…
0
8
48
Announcing atai Impact’s first initiative: the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics. Driving critical
#innovation
to meet urgent
#mentalhealth
needs
#ataiImpact
@MassGeneralNews
3
11
47
In response to the tragic events in Ukraine, we’re donating $100k through our philanthropic fund, atai Impact, to
@ICRC
,
@SaveChildren
,
@HelpAge
&
@LiberecoPHR
, towards emergency relief & supporting the
#mentalhealth
of the
#Ukrainian
people.
#StandwithUkraine
1
6
47
“Mental healthcare is likely the single largest unmet medical need in the world.
What’s out there now isn’t working. There are better options.
Millions of people deserve these options.”
-
@flobrand
, CEO and Co-Founder
4
4
48
Today, we received approvals to initiate the Phase 1 trial of EMP-01, an MDMA derivative, being developed for the treatment of
#PTSD
Phase 1 is a critical first step in establishing safety & tolerability. We look forward to results expected in H2 2023
6
13
44
We are pleased to announce positive topline results from our Phase 1 EMP-01 (R-MDMA) study.
“We found differences in the subjective experience of R-MDMA in comparison to published reports involving racemic MDMA. If confirmed, these differences suggest that R-MDMA may have…
0
9
45
Cognitive Impairment Associated with Schizophrenia is a debilitating disorder with no effective treatments.
We proudly announce a step towards bridging that gap, as Recognify initiates a Phase 2a study after receiving IND clearance.
Read more:
1
5
42
Today, we announced the initiation of a Phase 1 clinical trial of intranasal INB-01, a sol-gel based direct-to-brain drug-delivery technology.
Topline results are expected in H1 2023.
#mentalhealth
#biotech
#innovation
1
7
42
Following promising interim data from our RL-007 P2a trial, in Cognitive Impairment Associated with Schizophrenia, we are supporting acceleration of its clinical development.
Press release:
#schizophrenia
#mentalhealth
#clinicaltrials
1
12
42
Congratulations to our strategic investment
@COMPASSPathways
on announcing a multi-year partnership with
@KingsIoPPN
and
@MaudsleyNHS
. Collabs like this are key as we work towards better care for mental health.
4
6
43
Excited to announce initial results from
@BeckleyPsytech
's Phase 2a open label study of BPL-003 (intranasal 5-MeO-DMT) in patients who suffer from treatment-resistant depression (TRD).
The results offer encouraging support for a 2-hour psychedelic-based treatment in the…
0
11
42
Today we announced the initiation of a Phase 2b proof-of-concept clinical trial of RL-007 for Cognitive Impairment Associated with
#Schizophrenia
, for which there are currently no
@US_FDA
-approved treatments.
cc
@flobrand
@C_Angermayer
sub
#mentalhealth
2
11
39
Our vision is clear.
We work so that everyone, everywhere can live a more fulfilled life.
2
7
40
At atai, our motivation is personal.
Our CEO,
@flobrand
has a personal connection and motivation that inspired his commitment to improving treatments for mental health disorders.
Like Florian, we’re all committed professionally, and personally.
1
8
42
Our Founder & Chairman
@C_Angermayer
, is talking today at renowned US
@SALTConference
- testament to the growing ‘psychedelic renaissance’ & broadening interest in the potential of
#psychedelics
in the future of
#mentalhealth
treatment.
#OpenYourMind
#ApeironInvestments
1
11
42
Thrilled to announce our strategic investment in and collaboration with
@BeckleyPsytech
, bringing two clinical-stage psychedelic assets into the atai mental health innovation platform.
Join the webcast with our executive team today at 8am ET today to learn more.…
0
8
41
ICYMI: Last week we announced a strategic investment in
@BeckleyPsytech
, underscoring our conviction in psychedelics to transform the landscape of mental health treatments.
As covered by Bloomberg, the deal brings two patent-protected, clinical-stage, short-duration psychedelic…
0
11
39
A little history of
#psilocybin
to put today’s news, our increased stake in
@COMPASSPathway
in context.
#COMP360
#psychedelics
#mentalhealth
1
10
37
Our platform company Perception Neuroscience & Otsuka Pharmaceuticals join forces to develop & commercialize PCN-101 in Japan!
PCN-101 is a formulation of R-ketamine, being developed as a rapid acting antidepressant for potential at home use.
Read more:
0
5
38
Redefining how the world approaches, prevents, and heals
#mentalhealth
disorders.
Our mission is to bridge the gap between what the mental healthcare system currently provides and what patients need.
@C_Angermayer
@flobrand
@SriniGRao
@peterthiel
@novogratz
@FutureJurvetson
0
4
37
Read our latest white paper in
@Nature
chronicling the modern history of
#psychedelics
, their potential efficacy in solving the
#mentalhealth
crisis, and the path forward for moving from clinical trials through to patient access.
2
14
36
Today, we announced the results from the Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).
Read more:
#MentalHealth
#Biotech
#CollaborativeInnovation
0
11
36
Big news from our partners
@IntelGenx
! Huge congratulations on FDA approval - it's fantastic to see this innovative technology being used by those in need. Can't wait to see how what we'll accomplish together with our VLS-01 oral thin film formulation of DMT for the potential…
2
9
36
Today we announced our Q2 2022 earnings:
- Extended runway into 2025
- $312m cash + up to $175m non-dilutive debt
- Reprioritized pipeline w/ focus on clinical programs
- Hit 4 key R&D milestones and many expected PoC readouts in next 2 years
0
7
35
Today we announced our Q1 2022
#earnings
.
Read about the progress we’ve made across our 3 key pillars to deliver on our vision to achieve clinically meaningful behavioral change in people living with
#mentalhealth
disorders $ATAI
1
12
35
Congratulations
@COMPASSPathway
!
As an early and significant shareholder in the company, we are pleased leading healthcare investors are supporting mental health, psychedelic medicine, and interventional psychiatry.
Read more:
3
4
35
Today we announced results from the Kures Therapeutics Phase 1 Part 2 clinical trial of KUR-101, a deuterated derivative of mitragynine for the potential treatment of
#opioidusedisorder
cc
@flobrand
@C_Angermayer
@Allan_Malievsky
sub
#mentalhealth
#oud
10
6
34
We’re working to overcome the challenges of drug delivery for the treatment of mental health disorders. Watch to learn more about our enabling tech company, InnarisBio, with
@UniQuestUQ
, and our sol-gel intranasal drug delivery platform.
1
6
35
Mental health disorders such as depression, substance use disorder, and anxiety, which are among our initial indications of focus, are highly prevalent and estimated to affect more than one billion people globally.
0
6
34
Want to keep up with the ATAI team on Twitter? Let's connect!
@flobrand
, CEO
@SriniGRao
, CSO
@Roman_Dahl
, Operations Lead
@DannyTalati
, BD Lead
@gregulatory
, Regulatory Lead
@ph_schreiber
, BD
@SimonSeibold
, BD
@Allan_Malievsky
, Comms
#psychedelics
#mentalhealth
#TogetherAtHome
0
6
32
Today, we announced the completion of enrollment for a Phase 2a clinical trial of PCN-101, (R-ketamine), a stereoisomer of
#ketamine
, for treatment-resistant
#depression
(TRD).
To learn more, make sure you join our virtual R&D Day today @ 12pm ET!
2
5
34
Our Co-Founder & Chairman
@C_Angermayer
is the headline act today at the Grizzle Psychedelics Conference, speaking at 10:50 ET, telling the story & vision of
@atai_life
, front & center in the
#psychedelics
#mentalhealth
renaissance.
See more:
4
6
34
Today we’re pleased to share that the first patient has been dosed in our VLS-01 Phase 1b trial.
VLS-01 is being developed as a rapid-acting and durable antidepressant treatment intervention for people suffering from treatment resistant depression, a condition which affects…
0
11
33
HUGE ANNOUNCEMENT: This will accelerate our research into the therapeutic potential of psychedelics!
We’re thrilled to announce our collaboration with
@MassGeneralNews
and their newly established Center for the Neuroscience of Psychedelics.
Read more:
1
8
33
Today, we announced the completion of the Phase 1 study of VLS-01 (DMT) in healthy participants.
Our CEO and Co-Founder
@Flobrand
commented: “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/PD profile of our…
0
11
32
1
9
33
We are pleased to share our Q3 2023 update demonstrating the progress we’ve made in pursuit of our mission to heal mental health disorders. We advanced our key clinical programs, such as RL-007, VLS-01 and EMP-01, and continued to drive forward our drug discovery and preclinical…
0
10
32
#ICYMI
: Last week, we announced positive results from our Phase 1 clinical trial of GRX-917 for generalized anxiety disorder (GAD).
Initiation of GRX-917 efficacy study is anticipated in H1 2023, with results expected in 2024.
1
5
31
1 in 2 people globally will be diagnosed with a
#mentalhealth
disorder before they reach the age of 75.
With this in mind, today we shared our Q2 2023 financial results and business highlights, which demonstrate progress towards our mission of pioneering the development of the…
3
9
31
📣 BPL-003 clinical trial progress
A few weeks ago, we announced the positive results from the BPL-003 Phase 2a study in patients with treatment resistant depression who were not on oral antidepressants (SSRIs). The first patient has now been dosed in the second part of the…
0
10
33
Ketamine has been used for everything from anesthesia and sedation to chronic pain and severe treatment resistant depression.
1
7
32
MAJOR NEWS: A new addition to the atai family!
We’re thrilled to announce that we have acquired a majority stake in Recognify Life Sciences, focused on developing a treatment for Cognitive Impairment associated with Schizophrenia (CIAS).
(Read more below...)
3
4
32
In England, antidepressant usage has hit an all-time high.
But they are far from a one-size-fits-all solution.
SSRIs take anywhere from 3 weeks to 3 months + to have an effect.
And often, time isn't something that those battling with their mental health have in abundance.
1
5
31
DATA ALERT:
#COMP360
#psilocybin
P2b data show rapid & durable effects in TRD. Major news for
@COMPASSPathway
, atai & patients. Congratulations
@LarsWilde
, Ekaterina Malievskaia, George Goldsmith & team.
See:
#mentalhealth
#psychedelics
1
6
31
Apeiron Investment Group & other key pre-IPO investors have shown their strong confidence in
@atai_Life
, extending the lock-up on approx. 30% of overall equity. Clear demonstration of their shared belief in our vision & our ability to achieve it.
Read:
1
4
31
In the US, anxiety disorders affect approximately 40 million adults, or 18% of the population.
Only around a third of these people receive any treatment.
Without treatment, most anxiety disorders persist indefinitely.
Addressing this problem has never been more important.
1
6
30
Congratulations to
@COMPASSPathway
on their latest publication in
@JAMAPsych
, detailing the results of COMP360, psilocybin treatment, in bipolar type II depression. These early efficacy signals for such a hard-to-treat indication are encouraging.
0
9
29
Gem from
@andersoncooper
&
@michaelpollan
in recent
@60Minutes
on
#psychedelics
:
"Pollan experienced what researchers describe as ego loss, or identity loss (...)
AC: And what are you are without an ego?
MP: You're, uh… You had to be there."
1
9
29
A historic milestone by the
@COMPASSPathway
team!
@NEJM
has published positive results from COMPASS’ phase 2b trial of COMP360
#psilocybin
therapy for treatment-resistant
#depression
Congratulations from everyone at atai 👏👏👏
0
6
27
#ICYMI
:
@thetimes
' Science Editor
@Ben_Spencer
wrote a special report on
#mentalhealth
&
#psychedelics
“Between [atai and
@COMPASS
], the two companies have eight compounds in clinical trials, from MDMA [-derivative] and ibogaine to dimethyltryptamine.”
1
6
28
Boston-based grad students can now apply for the atai Fellowship in Psychedelic Neuroscience at
@MassGeneralNews
.
Fellows will investigate the potential of
#psychedelics
to improve 🧠 health and address the
#mentalhealth
crisis.
More info:
#ataiImpact
0
8
29
Marking
#WorldMentalHealthDay
by highlighting mental health issues for refugees and the displaced people around the world - people who have higher rates of mental health challenges because of the trauma they have faced, but less access to quality care.
2
4
28
People with treatment-resistant depression urgently need better options. PsyProtix will take a precision psychiatry approach, utilizing metabolomics to analyze diet exposome, gut microbiome, & genome to potentially tailor treatments to individuals.
3
7
29
Just in: post-hoc analyses of
#COMP360
P2b in TRD by
@COMPASSPathway
show further improvements in key areas central to
#patient
recovery:
#anxiety
, self-reported
#depression
, positive & negative affect, functioning & quality of life. Congrats again to all!
1
8
28
Our CEO and Co-Founder
@flobrand
spoke to
@amanda_siebert
@Forbes
to give deeper context on the significance of our donation to
@MAPS
and the importance of collaboration between for-profit and non-profits in tackling the
#mentalhealth
crisis.
See:
1
9
29
COMPANY UPDATES
1⃣ FPI in Ph2 study of RL-007 for CIAS
2⃣ Development plan to progress GRX-917 for
#anxiety
directly into Ph2
3⃣ Acceleration of CMPS Ph3
#psilocybin
program
4⃣ Pipeline updates to extend runway into 2026
#mentalhealth
#biotech
3
7
28
Today our co-founder and CSO
@SriniGRao
will give testimony alongside other experts on the scientific data of ibogaine as a potential treatment option for Opioid Use Disorder (OUD) behalf of the Kentucky Opioid Abatement Advisory Commission.
The Commission’s goal is to allocate…
3
9
26
This long-anticipated report from
@PierceARK
(via
@CathieDWood
's
@ARKInvest
) skillfully balances excitement re
#psychedelics
with a
#biotech
-focused analysis of the road ahead.
Grateful to the ARK team for helping educate the public!
#mentalhealth
8
5
27
Today we launch Invyxis, our latest addition to our suite of complementary tech for
#psychedelic
and nonpsychedelic drug discovery, to continue to pioneer next gen
#mentalheath
treatments for patients in need.
1
5
28
Thank you
@52_Insights
for hosting
@flobrand
&
@C_Angermayer
. This is the first time the two have appeared on a podcast together – which certainly makes for a fascinating conversation!
Listen here:
1
7
28
Announcing initiation of Phase 1/2a trial testing ibogaine for the treatment of opioid use disorder (OUD). Learn more about this naturally-occurring psychedelic, isolated from a West African shrub.
Press release:
#OpioidUseDisorder
#ibogaine
$ATAI
0
8
27
Today we announced our 2021 EOY & Q4
#earnings
. 2021 was a transformative year for atai. This positive momentum continues through 2022 & beyond. We are very well positioned to deliver on our vision: to heal
#mentalhealth
disorders $ATAI 1/2
1
5
28
We’re excited to announce the initiation of a clinical study with
@MassGeneralNews
to develop a novel method to detect
#neuroplasticity
in patients with
#TRD
undergoing IV
#ketamine
treatment.
1
2
25
Love this panel :)
@shelbyannehart
/
@doubleblindmag
injecting nuance as always and reminds us to be mindful that (nomatter where you fit on decrim/legalization/medicalization continuum) we in the
#psychedelics
community may be in a bit of a bubble (however large) 💭
@MicrodoseHQ
3
5
25
Welcome to all our new followers! Sign up to our
#InsightNetwork
where you can keep up with the latest events and news in biotech,
#mentalhealth
research, and
#psychedelic
science.
Sign up:
Read:
LinkedIn:
3
2
25
Has COVID-19 magnified depression? Yes, based on surveys, depression symptoms have increased 3X since the beginning of the COVID-19 pandemic, and severe depression symptoms have increased 7.5x.
1
7
25
A growing number of ex-troops are experiencing the healing power of
#psychedelics
.
“I believe I left my PTSD behind in those sessions. I am no longer destructive or closed off. I have my life back.”
By Jamie Doward for
@guardian
.
#psilocybin
#PTSD
0
11
25
This
#WorldMentalHealthDay
, hear from neuroscientist, clinical psychologist, and our scientific advisor
@heather_berlin
, and join us in our mission to
#healmentalhealth
for everyone everywhere.
0
9
25
We were saddened to learn of the recent passing of Roland Griffiths, Ph.D., Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine.
Dr. Griffiths leaves behind an unparalleled legacy of clinical trials and published…
0
9
25
So proud to welcome another member of the ATAI family: Viridia, developing N, N-Dimethyltryptamine (
#DMT
)!
We sat down w/
@amirahalidrus
of
@FierceBiotech
to share more about the potential of rapid-acting
#psychedelics
for
#mentalhealth
2
13
26
The Phase 1 results of BPL-003 (intranasal 5-MeO-DMT) have been published in the prestigious Journal of Psychopharmacology.
BPL-003 is currently being investigated by
@BeckleyPsytech
in Phase 2a studies as a potential treatment for Alcohol Use Disorder (AUD) and Treatment…
0
3
25
Personal insights and forward-looking thinking from our Chairman & Founder and industry visionary
@C_Angermayer
from his recent attendance of
@SALTConference
"Ultimately, I believe that
#mentalhealth
has 100% total addressable market because 100% of the people want to be healthy and happy. And if we are healthy and happy, we want to live forever, which is why my other big topic in biotech is longevity." $ATAI
61
1K
30K
3
6
23
Our Co-Founder & CEO
@flobrand
recently wrote to administrator
@AnneMilgram
and the
@DEAHQ
to encourage the agency to withdraw its proposed rule around placing two psychedelics – 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) – into schedule I.…
3
7
23
Today we shared our 2023 full year financial results and business highlights.
Our CEO
@FloBrand
commented: “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need. Much of our recent focus has centered on developing…
0
7
25
Inspired by this
@MayoClinic
article highlighting the misunderstanding and stigma that can make it difficult for people to seek mental health care, we got thinking about some of the ways we can take care of our mental well-being.
Here are 4 simple things…
0
9
20
Half of the world’s population will experience a mental health condition in their lifetime. This staggering statistic underscores the pressing need for innovative new approaches to both preventing and treating mental conditions.
That's why we're dedicated to developing new…
0
8
24
atai is proud to sponsor PSYCH’s The Psychedelics as Medicine Report, a leading publication on the renaissance of psychedelics and healthcare innovation. Be sure to check out the foreword from our CEO
@flobrand
@psychglobal_
0
7
23
ICYMI: some exciting news from us and
@BeckleyPsytech
this morning. Join us at 8am ET for a webcast with our executive team
@C_Angermayer
@flobrand
@SriniGRao
Full PR:
0
10
23
.
@FortuneMagazine
on
#psychedelics
for
#mentalhealth
at
@bstormhealth
:
There is “tremendous lack of innovation in psychiatric treatment. Only 7 neuropsychiatric drugs have [been] approved since 2015, while oncology has seen approval of 80 drugs”
@flobrand
1
3
22
“Mental health conditions are among the leading contributors to the global burden of disease.” (WHO Dir-Gen). Yet >75% of
#mentalhealth
patients are not treated effectively.
Our $atai Q1 23
#earnings
update demonstrates our commitment to
#innovation
.
Read the full PR here:…
0
5
23
Promising data out today from
@MDCancerCare
. Credit to the team & our joint co-founder
@LarsWilde
& team at
@CompassPathway
. These PII preliminary results are testament to the potential of
#psilocybin
&
#psychedelics
in medical
#mentalhealth
care. $ATAI
0
5
23
We are proud to be partnering with
@endwellproject
for the upcoming The End in Mind. Our CSO & Co-Founder,
@SriniGRao
, will be appearing on the panel: “Different lenses on psychedelics”.
Register for free using this link:
1
6
24
New positive data in our biomarker Ph2a of RL-007 in Cognitive Impairment Associated with
#Schizophrenia
show pro-cognitive profile. So we’re kicking off a double-blind, placebo-controlled Ph2a in
#cognition
. CIAS affects ~84% of people with schizophrenia
2
3
23
Today we announced positive initial results for our Phase 1 trial of KUR-101, an oral formulation of deuterated
#mitragynine
for the treatment of
#OUD
.
Topline results are expected by the end of the year.
cc
@flobrand
@SriniGRao
@C_Angermayer
0
2
23
Enabling technologies that aim to enhance the efficacy, safety, and tolerability of our drug candidates play an important role in development.
@IntelGenx
’s film technology fits nicely into atai’s growing platform of enabling technologies.
Read:
1
3
24
Perception Neuroscience’s PCN-101 (R-ketamine) has reached a significant milestone today, with the announcement of positive data from its Phase 1 clinical study demonstrating safety and tolerability.
Read more:
0
2
24
Important overview & call to action in
@TheLancet
by new Lancet-
@WPA_Psychiatry
Commission. Highlights prevalence & challenges of
#depression
, importance of multi-sectoral collaboration & moving beyond a one-size-fits-all approach.
#UniteAgainstDepression
Depression is overlooked & underfunded.
New Lancet-
@WPA_Psychiatry
Commission calls for whole-of-society approach to alleviate one of the world's leading causes of avoidable suffering & premature deaths.
#UniteAgainstDepression
➡️
11
306
519
1
6
24
Congrats to our CEO
@flobrand
(and
@rihanna
) for making
@FortuneMagazine
’s
#40under40
list of influential individuals shaping the world 🎉
We're so proud of you, Florian. Make sure you catch his talk on
#mentalhealth
at
#HLTH2022
@ 4:20pm PST today!
2
6
23
This
#VeteransDay
, we are honored to sponsor the
@vetsforvets
Gala for the second year running, supporting its mission to explore psychedelic-assisted treatment solutions for veterans with
#mentalhealth
needs and end the epidemic of veteran suicide.
👉
0
3
22